Материалы научно-медицинского форума «Шаг за шагом к вершине. Новые горизонты в терапии лимфопролиферативных заболеваний»

Proceedings of the Medical Research Forum “Step by Step to the Summit. New Horizons in the Therapy for Lymphoproliferative Diseases”

• Daria Aleksandrovna Koroleva National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

1. Brown JR, Seymour JF, Jurczak W, et al. Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial. Am Soc Hematol. 2024;144:1009–11.
2. Dreyling M, Doorduijn J, Giné E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403(10441):2293–306. doi: 10.1016/S0140-6736(24)00184-3.
3. Rule S, Dreyling M, Goy A, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179(3):430–8. doi: 10.1111/bjh.14870.
4. Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659–67. doi: 10.1016/S0140-6736(17)33108-2.
5. Kumar A, Soumerai J, Abramson JS, et al. A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in patients with treatment-naive, TP53-mutant mantle cell lymphoma. Am Soc Hematol. 2023;142:738–40.
6. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331–42. doi: 10.1056/NEJMoa1914347.